Literature DB >> 20211653

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

Darius Armstrong-James1, Justin Stebbing, Andrew Scourfield, Erasmus Smit, Bridget Ferns, Deenan Pillay, Mark Nelson.   

Abstract

Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20211653     DOI： 10.1016/j.antiviral.2010.02.324

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  16 in total

Review 1.  Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.

Authors:  Guoyan G Xu; Jia Guo; Yuntao Wu
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

Authors:  Maria Espirito-Santo; Quirina Santos-Costa; Marta Calado; Patrick Dorr; J Miguel Azevedo-Pereira
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-03       Impact factor: 2.205

4.  Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

Authors:  Robert A Smith; Dana N Raugi; Nancy B Kiviat; Stephen E Hawes; James I Mullins; Papa S Sow; Geoffrey S Gottlieb
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

5.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

6.  HIV-2 infection in Providence, Rhode Island from 2002 to 2011.

Authors:  B L Hollenbeck; C G Beckwith
Journal:  HIV Med       Date:  2012-05-11       Impact factor: 3.180

7.  Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

Authors:  Kevin Peterson; Sabelle Jallow; Sarah L Rowland-Jones; Thushan I de Silva
Journal:  AIDS Res Treat       Date:  2011-02-09

8.  HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Robert A Smith; Ndeye Mery Dia Badiane; Selly Ba; Stephen E Hawes; Macoumba Toure; Alison K Starling; Fatou Traore; Fatima Sall; Stephen L Cherne; Joshua Stern; Kim G Wong; Paul Lu; Moon Kim; Dana N Raugi; Airin Lam; James I Mullins; Nancy B Kiviat
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

Review 9.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

10.  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.

Authors:  Robert A Smith; Dana N Raugi; Charlotte Pan; Papa Salif Sow; Moussa Seydi; James I Mullins; Geoffrey S Gottlieb
Journal:  Retrovirology       Date:  2015-02-05       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.